Patents by Inventor John F. Kadow

John F. Kadow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10954252
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: March 23, 2021
    Assignee: ViiV HEALTHCARE UK (NO.5) LIMITED
    Inventors: Suresh Babu, Makonen Belema, John A. Bender, Christiana Iwuagwu, John F. Kadow, Selvakumar Kumaravel, Pulicharla Nagalakshmi, B. Narasimhulu Naidu, Manoj Patel, Kevin M. Peese, Ramkumar Rajamani, Mark Saulnier, Alan Xiangdong Wang
  • Publication number: 20210024503
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Application
    Filed: April 11, 2019
    Publication date: January 28, 2021
    Inventors: Makonen BELEMA, John A. BENDER, David B. FRENNESSON, Eric P. GILLIS, Christiana IWUAGWU, John F. KADOW, B. Narasimhulu NAIDU, Kyle E. PARCELLA, Kevin M. PEESE, Ramkumar RAJAMANI, Mark G. SAULNIER, Alan Xiangdong WANG, Manoj PATEL, Michael S. BOWSHER
  • Publication number: 20210023098
    Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, ?2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.
    Type: Application
    Filed: October 13, 2020
    Publication date: January 28, 2021
    Inventors: Yasutsugu UEDA, Timothy P. CONNOLLY, John F. KADOW, Nicholas A. MEANWELL, Tao WANG, Chung-Pin H. CHEN, Kap-Sun YEUNG, Zhongxing ZHANG, David Kenneth LEAHY, Shawn K. PACK, Nachimuthu SOUNDARARAJAN, Pierre SIRARD, Kathia LEVESQUE, Dominique THORAVAL
  • Publication number: 20200325127
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Application
    Filed: May 9, 2017
    Publication date: October 15, 2020
    Inventors: John F. KADOW, B Narasimhulu NAIDU, Tao WANG, Zhiwei YIN, Zhongxing ZHANG
  • Publication number: 20200291002
    Abstract: The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: March 17, 2017
    Publication date: September 17, 2020
    Inventors: Kap-Sun Yeung, John F. Kadow, Rajesh Onkardas Bora, Prakash Anjanappa, Kumaravel Selvakumar, Samayamunthula Venkata Satya Arun Gupta
  • Patent number: 10577353
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: March 3, 2020
    Assignee: ViiV HEALTHCARE UK (NO.5) LIMITED
    Inventors: John F. Kadow, B. Narasimhulu Naidu, Tao Wang, Zhiwei Yin, Zhongxing Zhang
  • Patent number: 10570108
    Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: February 25, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhiwei Yin, John F. Kadow
  • Publication number: 20200055839
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Application
    Filed: January 2, 2018
    Publication date: February 20, 2020
    Inventors: Makonen BELEMA, Michael S. BOWSHER, Jeffrey A. DESKUS, Kyle J. EASTMAN, Eric P. GILLIS, David B. FRENNESSON, Christiana IWUAGWU, John F. KADOW, B. Narasimhulu NAIDU, Kyle E. PARCELLA, Kevin M. PEESE, Mark G. SAULNIER, Prasanna SIVAPRAKASAM
  • Publication number: 20200046743
    Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.
    Type: Application
    Filed: October 22, 2019
    Publication date: February 13, 2020
    Inventors: Yasutsugu UEDA, Timothy P. CONNOLLY, John F. KADOW, Nicholas A. MEANWELL, Tao WANG, Chung-Pin H. CHEN, Kap-Sun YEUNG, Zhongxing ZHANG, David Kenneth LEAHY, Shawn K. PACK, Nachimuthu SOUNDARARAJAN, Pierre SIRARD, Kathia LEVESQUE, Dominique THORAVAL
  • Patent number: 10407410
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: September 10, 2019
    Assignee: ViiV HEALTHCARE UK (NO.5) LIMITED
    Inventors: John F. Kadow, B. Narasimhulu Naidu, Manoj Patel, Michael A. Walker, Tao Wang, Zhiwei Yin, Zhongxing Zhang, Zhizhen Barbara Zheng
  • Patent number: 10351546
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: July 16, 2019
    Assignee: ViiV HEALTHCARE UK (NO. 5) LIMITED
    Inventors: Kyle J. Eastman, John F. Kadow, B. Narasimhulu Naidu, Kyle E. Parcella, Manoj Patel, Prasanna Sivaprakasam, Yong Tu
  • Publication number: 20190152957
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Application
    Filed: May 9, 2017
    Publication date: May 23, 2019
    Inventors: John F. KADOW, B. Narasimhulu NAIDU, Tao WANG, Zhongxing ZHANG
  • Publication number: 20190127351
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Application
    Filed: May 9, 2017
    Publication date: May 2, 2019
    Inventors: John F. KADOW, B. Narasimhulu NAIDU, Manoj PATEL, Michael A. WALKER, Tao WANG, Zhiwei YIN, Zhongxing ZHANG, Zhizhen Barbara ZHENG
  • Publication number: 20190111066
    Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.
    Type: Application
    Filed: November 14, 2018
    Publication date: April 18, 2019
    Inventors: Yasutsugu UEDA, Timothy P. CONNOLLY, John F. KADOW, Nicholas A. MEANWELL, Tao WANG, Chung-Pin H. CHEN, Kap-Sun YEUNG, Zhongxing ZHANG, David Kenneth LEAHY, Shawn K. PACK, Nachimuthu SOUNDARARAJAN, Pierre SIRARD, Kathia LEVESQUE, Dominique THORAVAL
  • Publication number: 20190092754
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Application
    Filed: November 28, 2018
    Publication date: March 28, 2019
    Inventors: Kyle J. EASTMAN, John F. Kadow, Kyle E. Parcella, B. Narasimhulu Naidu, Tao Wang, Zhiwei Yin, Zhongxing Zhang
  • Patent number: 10221156
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: March 5, 2019
    Assignee: VIIV HEALTHCARE UK (NO.5) LIMITED
    Inventors: John F. Kadow, B. Narasimhulu Naidu, Manoj Patel, Prasanna Sivaprakasam
  • Patent number: 10214534
    Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: February 26, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhongxing Zhang, Kyle E. Parcella, Kyle J. Eastman, John F. Kadow
  • Patent number: 10214516
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: February 26, 2019
    Assignee: VIIV HEALTHCARE UK (NO.5) LIMITED
    Inventors: John F. Kadow, B. Narasimhulu Naidu, Tao Wang, Zhiwei Yin, Zhongxing Zhang
  • Patent number: 10202403
    Abstract: Compounds of formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: February 12, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhongxing Zhang, John F. Kadow
  • Patent number: 10189816
    Abstract: Disclosed are compounds of Formula (I), including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: January 29, 2019
    Assignee: ViiV HEALTHCARE UK (NO. 5) LIMITED
    Inventors: Kyle J. Eastman, John F. Kadow, Kyle E. Parcella, B. Narasimhulu Naidu, Tao Wang, Zhiwei Yin, Zhongxing Zhang